BINAP: Common Difficulties Encountered by Purchasers During Product Selection & HiSiaddi’s Solutions

As a new type of foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of BINAP from multiple well-known brands. As a R&D-focused foreign trade service provider, HiSiaddi professionally sorts out common challenges faced by B-end purchasers sourcing BINAP from China and proposes targeted solutions from a technical perspective.

If you require more professional and in-depth analysis regarding BINAP procurement, please contact HiSiaddi customer service. [Structural formula image of BINAP]

I. European & American High-End Pharmaceutical Enterprises (Chiral Drug Mass Production, Asymmetric Hydrogenation/Reduction Processes, FDA/EMA Compliance)

(I) Core Pain Points

Insufficient chiral purity leading to ineffective drugs / excessive toxicity, trace heavy metal residues triggering pharmaceutical authority recalls, excessive solvent residues failing GMP audits, batch-to-batch ee value fluctuations disrupting process stability, and supply chain disruptions halting production lines

1. Substandard chiral purity (ee value): Excessive (R)/(S)-BINAP enantiomeric impurities (ee < 99.5%) result in insufficient drug enantiomeric purity, ranging from reduced efficacy to toxic side effects, directly violating FDA/EMA pharmacopoeia standards and barring finished product market launch.

2. Heavy metal residue risks: Heavy metals such as Fe, Pb, Ni (>5ppm) integrate into drug molecules during catalytic reactions, causing finished product heavy metal overload, triggering pharmaceutical authority recalls and incurring massive financial losses.

3. Excessive organic solvent residues: Residual toluene, dichloromethane and other solvents exceeding ICH Q3C limits fail GMP workshop audits and restrict production qualifications.

4. Batch-to-batch chiral purity fluctuations: >0.3% variance in ee value and chemical purity across batches causes unstable reaction selectivity under fixed catalytic processes, inconsistent drug yield and purity, and impedes large-scale mass production.

5. Fragile supply chain: Concentrated global production capacity, high technical barriers for chiral resolution and environmental regulations create high supply disruption risks. Out-of-stock incidents halt high-value production lines with daily losses reaching millions of euros.

(II) Targeted Solutions

1. Rigorous chiral purity control: Coupled high-efficiency chiral resolution and recrystallization processes stabilize BINAP (R)/(S) chiral purity at ≥99.8% ee, with chiral HPLC spectra supplied for every batch to meet stringent pharmacopoeia requirements.

2. Deep heavy metal removal: Custom chelating resin adsorption + precision filtration processes reduce total heavy metals to <1ppm, with ICP-MS test reports provided to eliminate pharmaceutical authority risks.

3. Strict residual solvent control: High-vacuum gradient solvent removal + inert gas purge technology cuts solvent residues to <100ppm in compliance with ICH Q3C standards, with GC-MS residual solvent reports accompanying shipments.

4. Batch consistency guarantee: Fully automated closed-loop production locks core resolution, crystallization and drying parameters, restricting ee value and purity variance between batches to <0.1% for stable catalytic processes.

5. Dedicated production capacity reservation: 5 tons/year exclusive production capacity reserved with long-term supply agreements and safety stock equal to ≥3 months’ consumption; delivery lead times capped at 15 days to eliminate supply disruptions.

II. European & American Fine Chemical & Special Material Enterprises (High-End Intermediates, Optoelectronic Materials, Small-Batch Custom Asymmetric Catalysis)

(I) Core Pain Points

Trace phosphine oxide impurities reducing catalytic activity, powder agglomeration causing uneven feeding, difficulty sourcing small-batch high-purity custom grades, oxidation-induced deterioration shortening shelf life, and insufficient technical support for process adaptation

1. Catalytic activity impairment from phosphine oxide impurities: Oxidation of BINAP generates phosphine oxides (>0.5%) that occupy catalytic active sites, cutting catalytic efficiency by over 30% and drastically lowering reaction conversion and selectivity.

2. Uneven feeding from powder agglomeration: Ultra-fine powder agglomerates during storage and transportation, causing inconsistent dosing in automated feeding systems, unbalanced reaction ratios and fluctuating finished product purity across batches.

3. Barriers to small-batch high-purity customization: R&D and lab-scale trials require small lots (10g–5kg) of ultra-high purity (≥99.9%) BINAP, yet most suppliers only offer large-pack industrial grade products with long customization lead times and high minimum order quantities.

4. Poor stability and oxidative deterioration: Standard packaging lacks sufficient light and oxygen isolation; products rapidly oxidize and yellow after opening, losing catalytic activity with shelf lives under 6 months, failing long-term laboratory sample retention requirements.

5. Lack of technical support: Suppliers only provide basic COAs without catalytic compatibility data, impurity traceability or process optimization recommendations, delaying adaptation to clients’ proprietary catalytic systems.

(II) Targeted Solutions

1. Oxidized impurity control: Full-process nitrogen/argon protected production with dedicated anti-oxidant stabilizers limits phosphine oxide content to <0.2% for stable catalytic activity.

2. Anti-agglomeration powder treatment: Jet milling + surface modification delivers loose, non-agglomerated powder with uniform particle size distribution (D50=5–10μm), compatible with automated feeding and precise reaction dosing.

3. Flexible small-batch customization: Dedicated R&D production lines support orders starting at 10g, offering multiple purity grades from 99% to 99.9% with 48-hour response and 7-day delivery to match lab/pilot scale demands.

4. High-stability packaging: Aluminum cans lined with double-layer light-proof moisture-resistant film and argon-sealed packaging with built-in color-changing silica gel deliver a minimum 24-month ambient shelf life; secondary sealing after opening slows oxidation.

5. Dedicated technical service: In-house chiral catalysis technical teams provide full impurity profile analysis, catalytic compatibility reports and process optimization schemes with full trial production tracking to resolve technical challenges.

III. Indian & Southeast Asian Pesticide & General Fine Chemical Enterprises (Cost-Oriented, Large-Volume Racemic (±)-BINAP, Mid-to-Low-End Catalysis)

(I) Core Pain Points

High costs of high-purity chiral monomers squeezing profit margins, excessive impurities in racemates lowering reaction efficiency, large-batch quality fluctuations requiring frequent process parameter adjustments, oxidative agglomeration under high-temperature high-humidity transportation & storage, and missing compliance documentation blocking local registration

1. Cost pressure from high-purity chiral monomers: Premium (R)/(S)-BINAP chiral monomers carry high prices that erode profit margins for pesticide and general fine chemical production; low-cost crude products contain excessive impurities unsuitable for manufacturing standards.

2. Reduced efficiency from racemate impurities: (±)-BINAP raw materials with high phosphine oxide and heavy metal impurities lower catalytic reaction efficiency, increase byproduct formation and produce substandard finished products with weak market competitiveness.

3. Large-batch quality instability: Fluctuations in purity, water content and impurities across ton-scale shipments force repeated adjustments to reaction temperature and dosing ratios, frequent production line shutdowns for calibration and low equipment utilization rates.

4. Oxidation and agglomeration during storage & transportation: High-temperature high-humidity shipping routes to Southeast Asia and India paired with poor packaging sealing cause raw materials to absorb moisture, oxidize and agglomerate, losing catalytic activity upon arrival and generating high cargo loss rates.

5. Missing compliance documentation: Lack of English COAs, MSDS and basic test reports blocks local industrial registration and sampling inspections, restricting product market circulation.

(II) Targeted Solutions

1. Cost-effective industrial grade solution: Industrial grade (±)-BINAP with ≥98.5% purity eliminates costly chiral resolution steps, priced 60% lower than chiral monomers to balance quality and cost.

2. Control of critical impurities: Optimized basic impurity removal processes cap phosphine oxides at <1% and heavy metals at <10ppm to stabilize catalytic efficiency, reduce byproducts and maintain consistent finished product quality.

3. Standardized locked-parameter mass production: Standardized production workflows unify purity, water content and impurity indicators, restricting batch variance to reasonable ranges to enable fixed production processes and minimize calibration downtime.

4. Moisture & oxidation resistant packaging: Thickened iron drums lined with moisture-resistant film and desiccants enhance oxygen and moisture isolation to withstand high-temperature high-humidity ocean shipping and guarantee consistent quality upon arrival.

5. Streamlined compliance document packages: English COAs, MSDS and basic test spectra supplied to satisfy local registration and sampling inspection requirements and facilitate market circulation.

IV. European & American Universities & Research Institutions (Academic Research, Chiral Catalysis Mechanism Studies, Journal Publication, Pharmacopoeia Reference Standards)

(I) Core Pain Points

Scarcity of ultra-high purity grades, trace unknown impurities skewing experimental results, imprecise chiral purity data, rapid oxidation during long-term storage, and insufficient supporting research data to support academic publications

1. Limited supply of ultra-high purity research grades: Cutting-edge research requires BINAP with ≥99.95% chemical purity and ≥99.9% ee chiral purity, unavailable from mainstream industrial/reagent grade suppliers with tight ultra-high purity supply.

2. Experimental interference from trace impurities: Trace unknown organic impurities and oxidation byproducts skew catalytic mechanism research and electrochemical testing, generating unreproducible experimental data and invalidating journal conclusions.

3. Imprecise chiral purity characterization: Conventional suppliers only provide single-point HPLC data without full-wavelength scanning or impurity peak assignment, delivering low-credibility chiral purity data failing rigorous academic standards.

4. Poor long-term storage stability: Standard packaging accelerates oxidation and discoloration, unable to support laboratory sample retention (≥1 year) and repeated experimental replication.

5. Insufficient supporting research data: Missing full impurity profiles, thermal/photostability data and catalytic kinetic curves hinder journal publication and research project filing.

(II) Targeted Solutions

1. Exclusive ultra-high purity research grade: Independent ultra-high purity production lines supply BINAP with ≥99.95% chemical purity and ≥99.9% ee chiral purity exclusively for academic research and reference standard preparation.

2. Full qualitative & quantitative impurity profiling: GC-MS, LC-MS and ICP-MS full impurity profiles provided for every batch to identify impurity types and concentrations, ensuring precise, reproducible experimental data.

3. Precise chiral characterization: Full-wavelength scanning chiral HPLC paired with NMR validation delivers detailed chiral purity reports with impurity peak assignment and integration data to meet academic rigor standards.

4. Research-grade stable packaging: 1g–100g small-format argon-sealed glass ampoules with complete light and oxygen isolation deliver a minimum 24-month ambient shelf life for long-term sample retention.

5. Full supporting research data: TGA thermogravimetric analysis, DSC differential scanning calorimetry, catalytic kinetic curves and stability investigation reports accompany shipments to support journal publication and research project archiving.

V. Overseas Chemical Packagers & Trading Companies (Regional Distribution, Multi-Size Repackaging, Chiral Ligand Circulation)

(I) Core Pain Points

Counterfeit low-quality goods falsely labeled with inflated purity metrics, severe compaction & agglomeration of large packaging hindering repackaging, quality degradation via oxidation during storage & transportation, incomplete hazardous chemical compliance documentation limiting market channels, and absence of third-party test reports losing high-end client orders

1. Falsified indicator labeling: Market prevalence of crude products falsely marketed as high-purity grades and racemates misrepresented as chiral monomers with inflated ee and purity values, leading to scrapped downstream products, equipment failure, compensation claims and damaged brand reputation.

2. Difficult repackaging of compacted large packaging: Long-term stacking compacts 25kg/50kg bulk packaging into solid blocks; secondary crushing for repackaging reduces efficiency and introduces extraneous impurities compromising product quality.

3. Quality degradation via oxidation during storage & transportation: Poor packaging sealing allows air and moisture infiltration during cross-border ocean shipping and warehousing, reducing purity and yellowing product color for rejection by high-end clients and substantial cargo losses.

4. Incomplete compliance documentation: Classified as flammable solid/organophosphorus compound, missing English SDS, REACH screening reports and marine hazard identification certificates block access to formal European and American supply chains, restricting sales to low-end markets only.

5. Lack of authoritative third-party test reports: Absence of full-item testing from accredited bodies (SGS, Intertek, etc.) prevents passing supplier audits by leading enterprises and forfeits high-value orders.

(II) Targeted Solutions

1. Authentic original factory supply: Direct sourcing from original manufacturers with fully accurate labeling of all indicators (purity, ee value, impurities); third-party full-item test reports supplied per batch supporting global re-inspection to eliminate counterfeit and mislabeled products.

2. Anti-compaction loose powder treatment: Anti-compaction and anti-agglomeration processing at manufacturing delivers loose bulk powder requiring no crushing prior to repackaging, avoiding secondary impurity contamination.

3. Full-process oxygen & moisture isolation: Uniform argon vacuum-sealed packaging delivers robust air and moisture barrier properties to inhibit oxidative deterioration, maintaining consistent quality matching factory standards upon arrival.

4. One-stop compliance documentation package: English SDS, REACH compliance statements, marine hazard identification certificates and COAs supplied to support market expansion into high-end European and American segments.

5. Complete traceability system: Batch traceability archives containing production records, quality inspection data and third-party reports support client factory audits and supplier qualification reviews to secure long-term cooperative partnerships.

For more professional and in-depth analysis of BINAP procurement, please contact HiSiaddi customer service.

Lead time

The monthly inventory volume of BINAP is 3 tons, with appropriate adjustments upwards or downwards in response to peak and off-peak seasons.

HiSiaddi safeguards the supply stability of BINAP through the following measures:

1. Supply of one mainstream BINAP model by 3 premium factories

(1) Performance evaluation and screening of BINAP brand factories based on on-time delivery rate, batch pass rate, timeliness of risk alerts, and completeness of documentation to assess their supply stability.

(2) For each mainstream model or major grade of BINAP, secure 1 primary high-quality brand manufacturer and 2 backup high-quality manufacturers.

(3) Each factory operates independent production lines in separate production zones to prevent production halts caused by major unforeseen incidents such as environmental production suspensions and power outages.

2. Technological transformation partnerships and long-term sales binding for BINAP

Through long-term cooperation with brand manufacturers via technology commercialization and authorized distribution channels, HiSiaddi can effectively strengthen supervision over the production processes of brand manufacturers, optimize full-process traceability management, improve batch stability control, and further reinforce real-time monitoring of the supply stability of BINAP products.

Long-term Annual Framework Supply Guarantee Agreement. HiSiaddi signs 12-month long-term agreements with leading manufacturers. The agreements specify the minimum guaranteed supply volume, maximum price hike range, and priority production scheduling rights during peak seasons. It is stipulated that manufacturers shall issue a 30-day prior written notice if production is suspended due to environmental rectification or equipment maintenance, and backup manufacturers will be activated to replenish goods accordingly.

3. 4 warehouses and 3 peak & off-peak demand forecasting

We have 4 warehouses, which are jointly operated and managed with suppliers to store hot-selling products.The four warehouses are located at Qingdao Port in North China, Ningbo Port in East China, Shenzhen Port in South China, and Zhengzhou, China’s inland logistics hub. This setup guarantees sufficient supply and timely shipment of BINAP during peak seasons.

HiSiaddi issues a rolling demand forecast covering the subsequent three months on the 25th of each month, allowing manufacturers to reserve production capacity in accordance with the forecast. Any new urgent orders from overseas clients will be prioritized to draw on inventories or production capacity from backup manufacturers.

4. Multi-channel logistics to resolve vessel congestion and inspection delays for BINAP sea and land shipments

Unstable logistics for BINAP will extend delivery lead times. HiSiaddi has established alternative arrangements covering multiple freight forwarders, ports and transportation solutions:

(1) Binding of multiple professional chemical freight forwarders for BINAP

Each product is assigned 2 to 3 freight forwarders with hazardous chemical/food transport qualifications affiliated with different shipping lines. Alternative sailing schedules can be switched to immediately in case of space shortages or customs inspections on a single shipping route.

(2) Backup transportation solutions for BINAP

Ocean freight serves as the standard mode; air freight and rail freight are reserved as alternatives for urgent orders. Long-term agreements for temperature-controlled containers are signed for temperature-sensitive and perishable food additives to secure shipping space.

(3) Visual tracking and digital early warning for BINAP

Freight forwarders synchronize daily updates on container loading, customs declaration, vessel loading and port arrival milestones. If customs inspection occurs, replenishment from backup inventory will be initiated immediately to shorten client waiting periods.

Full-chain digital early warning automatically monitors four categories of risks:

• Factory side: Expiring supplier environmental assessment certificates, renewal of production permits, scheduled major equipment overhauls, and notifications of price hikes for upstream raw materials;

• Inventory side: Inventory falling below safety thresholds, excessive inventory age, and batches failing quality inspection;

• Logistics side: Shipping line space shortages, strikes at destination ports, and updates to customs policies;

• Overseas side: Revisions to additive regulations and adjustments to import restriction lists in target countries.

Early warning notifications are automatically pushed to procurement and business leads, allowing backup suppliers or inventory contingency plans to be activated in advance.

BINAP: What Qualifications and Certifications Have Major Chinese Brands Obtained? What Is Their Market Feedback?

As a new-type foreign trade service provider driven by both technology transformation and export business, HiSiaddi has built a "1+2+3+4=1" service system and can supply BINAP sourced directly from multiple well-known original manufacturers.

As an export service provider with in-house R&D capabilities, HiSiaddi differs from single-brand factories that only promote their own products. We provide objective analysis of multiple competitive leading Chinese BINAP export brands and share their certification credentials and market feedback, enabling buyers to make more efficient, reliable purchasing decisions.

For more authentic, objective profiles of major Chinese BINAP brands, please contact HiSiaddi customer service.

I. Joysun Pharma (JOYCHEM): Domestic Benchmark for Ultra-High Purity BINAP, Core Supplier for Global Innovative Pharma

Core Export Grades

· JZ-BINAP-999 (R/S single enantiomer, ≥99.9% ee): Ultra-high pharmaceutical grade for asymmetric hydrogenation in anti-tumor and neurological innovative drugs, batch sizes ranging from 10 g to 50 kg, flagship grade compliant with European and U.S. pharmacopoeias.

· JZ-BINAP-995 (racemic, ≥99.5% ee): Industrial pharmaceutical grade widely used by generic drug CDMOs with stable ton-scale delivery capacity.

· JZ-MeO-BINAP (methoxy-substituted derivative, ≥99.8% ee): Custom high-activity ligand tailored for ADCs and chiral antibiotics, with export growth exceeding 40% in 2025.

Global B-End Market Feedback

· Multinational pharmaceutical companies (Novartis, Roche): Zero quality complaints for three consecutive years; batch-to-batch optical purity fluctuation limited to ±0.05%, outperforming equivalent grades from Japan’s Takasago. Raw material costs dropped by 22% post-import substitution, and this brand accounted for 65% of their ultra-high purity BINAP procurement volume in 2025.

· European and American CDMOs (Switzerland, Germany, U.S.): Stable delivery within 4 weeks for small-batch custom orders; heavy metal levels ≤5 ppm and residual solvents ≤0.1%, fully compliant with USP/EP standards. 92% repeat purchase rate in 2025, designated as the primary ultra-high purity BINAP supplier by three top-tier CDMOs.

· Global Market Share & Reputation: Ranked first in China’s BINAP export volume (38%) in 2025; captures 51% of the global ultra-high purity (≥99.9% ee) market. Named the domestic benchmark for chiral ligand localization by Frost & Sullivan.

Verifiable Authoritative Qualifications

· International Compliance Certifications: FDA cGMP, EU EDQM CEP, ISO 13485; directly applicable for European and U.S. pharmacopoeia-grade API production. Passed 12 European and U.S. official audits with a 100% pass rate in 2025.

· Green & ESG Credentials: EcoVadis Gold Medal (2025), SBTi greenhouse gas emission reduction certification; three-waste discharge surpasses EU standards, recognized as an ESG responsible enterprise.

· Technical Patents: 12 core BINAP patents covering continuous flow synthesis, solvent recycling and high enantioselective resolution; National Intellectual Property Demonstration Enterprise; broken Western monopolies on ultra-high purity BINAP technology.

II. Asymchem (KELUN): Integrated CDMO Supporting Leader, Dual Advantages of Stable Supply + Technical Services

Core Export Grades

· KL-BINAP-GMP (R/S single enantiomer, ≥99.8% ee): Manufactured in GMP workshops to support global CDMO projects, batch sizes 5–20 kg with 3–4 week lead times.

· KL-BINAP-TECH (racemic, ≥99.0% ee): Industrial grade with prominent price advantages for large-scale generic drug production; Southeast Asia accounted for 40% of its exports in 2025.

· KL-Ru-BINAP (RuCl₂-BINAP complex, ≥99.0%): Pre-catalyzed ruthenium complex streamlining client processes, boosting reaction conversion rates by 5%–8%, flagship supporting grade for CDMOs.

Global B-End Market Feedback

· Top 20 global pharmaceutical companies (16 active partners): Zero delivery delays for BINAP-supported CDMO projects; overseas CDMO orders rose 35% year-on-year in 2025, named the most reliable ligand supplier by Eli Lilly and AstraZeneca.

· Indian / Southeast Asian generic manufacturers: Industrial-grade pricing 28% lower than Western brands; consistent batch quality with impurity fluctuations ≤0.3%. Captured 40% of India’s market share in 2025 with an 88% repeat purchase rate.

· Technical Service Reputation: Offers catalytic process optimization, impurity spectrum analysis and lab-to-production scale-up support; client reaction conversion rates improve by 5%–8% on average; awarded Global Preferred Technical Service Provider.

Verifiable Authoritative Qualifications

· International Compliance Certifications: FDA cGMP, Japan PMDA, South Korea MFDS, ISO 9001/14001; fully aligned with ICH Q7. Passed over 100 official audits with 100% compliance since 2011.

· Industry Standing: Ranked second in China’s BINAP export volume (21%) in 2025; holds 18% of the global CDMO-supported BINAP market; world’s second-largest small-molecule CDMO.

· Technical Honors: AsymBio platform shortlisted for Best ADC Platform Technology at the World ADC Awards; chemoenzymatic processes achieve ≥99% conversion rates while cutting solvent consumption by 30%–50%.

III. WuXi AppTec (WUXI APPTECH): Full Product Coverage + Ultra-Fast Delivery, Preferred R&D-Grade Ligand Supplier

Core Export Grades

· WM-BINAP-999 (R/S single enantiomer, ≥99.9% ee): Ultra-high purity R&D grade with 7-day ultra-fast delivery for batches 1 g–1 kg, primary choice for pre-clinical screening with an 89% repeat purchase rate among global biotechs.

· WM-BINAP-990 (racemic, ≥99.0% ee): Ton-scale industrial grade with strong price competitiveness for liquid crystal / optical material applications.

· WM-SEGPHOS/BINAP hybrid ligand (≥99.5% ee): Specialized for asymmetric cyclization, core procurement grade for Japanese and South Korean liquid crystal manufacturers, capturing 35% of the Japan-South Korea market in 2025.

Global B-End Market Feedback

· Global Biotechs / R&D Institutions (3,000+ clients): 7-day ultra-fast delivery for 1 g–1 kg batches; full COA, NMR, HPLC and chiral chromatography data provided with every shipment; top pick for pre-clinical screening with an 89% repeat purchase rate in 2025.

· Japanese & South Korean New Material Manufacturers (Liquid Crystals / Optical Polymers): Hybrid ligands exhibit optical purity fluctuations ≤0.1% and superior high-temperature stability; secured qualified supplier status with JNC and LG Chemical, holding 35% regional market share in 2025.

· Global Market Share: Ranked third in China’s BINAP export volume (15%) in 2025; captures 22% of the global small-molecule building block BINAP market; serves over 6,000 clients including all Top 20 pharmaceutical firms worldwide.

Verifiable Authoritative Qualifications

· International Compliance Certifications: FDA cGMP, ISO 9001/14001, REACH, TSCA; meets global R&D reagent standards.

· Industry Awards: Frost & Sullivan 2025 Global CRDMO of the Year Award (9 consecutive years); CDP Climate Change A Rating (highest tier).

· Technical Capabilities: Mature continuous flow microreactor technology slashes BINAP synthesis costs by 18%; National Fine Chemical Innovation Enterprise of China.

IV. Funokang (FNK): Cost-Effective Industrial-Grade Leader, Top Choice for Large-Scale Generic Drug Production

Core Export Grades

· FNK-BINAP-995 (racemic, ≥99.5% ee): Ultra-cost-effective industrial grade with ton-scale production capacity, primary supplier for Indian and South American generic manufacturers, capturing 45% of India’s market in 2025.

· FNK-BINAP-R/S (single enantiomer, ≥99.0% ee): Mid-tier pharmaceutical intermediate with prices 40% lower than ultra-high purity alternatives, delivering outstanding cost performance.

· FNK-Pd-BINAP (palladium complex, ≥98.0%): Specialized for C–C coupling reactions, used in dye / fragrance intermediates; agrochemical applications account for 30% of its exports.

Global B-End Market Feedback

· Indian & South American Generic Manufacturers: Lowest global pricing with maximum production capacity (50 tons annual output); ton-scale orders delivered within 3 weeks; free chloride levels ≤8 ppm (industry average: 22 ppm), drastically mitigating metal residue risks. Held 45% of India’s market share in 2025.

· Agrochemical Enterprises (Brazil, Argentina): Consistent impurities ≤0.5% compatible with asymmetric pesticide synthesis; agrochemical applications made up 30% of total exports in 2025 with an 85% repeat purchase rate.

· Quality Reputation: Zero major quality incidents for five consecutive years; named Best Low-Cost Stable Supplier by the Indian Generic Drug Association.

Verifiable Authoritative Qualifications

· Domestic Certifications: ISO 9001/14001; China Top 100 Fine Chemical Enterprises; Baoji High-Tech Enterprise.

· Capacity Recognition: China’s largest industrial-grade BINAP producer with a 50-ton annual capacity accounting for 40% of China’s total industrial-grade output.

· Process Certifications: Fully closed phosgene-substituted production lines; industry-leading free chloride control ≤8 ppm.

V. Runfeng (RUNFENG): Custom Derivative Specialist, Front-Runner in Niche High-End Segments

Core Export Grades

· RF-BINAP-998 (R/S single enantiomer, ≥99.8% ee): Ultra-high purity custom grade for small batches 5 g–5 kg, tailored for rare disease / specialty drugs with a 95% repeat purchase rate among European niche pharmaceutical firms in 2025.

· RF-Alkyl-BINAP (alkyl-substituted derivative, ≥99.5% ee): High-temperature catalytic grade with exceptional stability for specialty fine chemical manufacturing.

· RF-BINAP-Salt (sulfonate salt derivative, ≥99.0%): Water-soluble variant for biocatalysis; custom derivative orders rose 40% year-on-year in 2025.

Global B-End Market Feedback

· European Niche Pharmaceutical Manufacturers (Rare Disease / Orphan Drugs): Superior customization capacity enabling substituent adjustments aligned with reaction conditions; stable purity ≥99.5% with fully controllable impurities. Captured 28% of Europe’s niche rare disease drug ligand market in 2025 with a 95% repeat purchase rate.

· Specialty Fine Chemical Producers (Chiral Intermediates / Fragrances): Derivatives deliver high catalytic activity and stability compatible with extreme reaction conditions; custom derivative orders grew 40% year-on-year in 2025.

· Delivery Reputation: 4–6 week custom synthesis cycles with strict technical confidentiality; recognized as the most reliable chiral ligand custom manufacturer.

Verifiable Authoritative Qualifications

· Customization Credentials: ISO 9001; National Benchmark Enterprise for Custom Chiral Ligands in China.

· Technical Patents: 8 proprietary BINAP derivative patents covering alkyl, sulfonate and fluorinated series; National Invention Patent Excellence Award.

· Client Recognition: Serves 500+ specialty chemical clients; exclusive custom ligand supplier for 3 European rare disease pharmaceutical manufacturers.

VI. Core Differentiation & Optimal Application Scenarios for the Five Brands (Quick Selection Reference)

1. Joysun Pharma: Ultra-high purity (≥99.9% ee) + full compliance + ultra-stable batch consistency | Best for innovative drugs, European & American CDMOs | Rating: ★★★★★

2. Asymchem: GMP-compliant + full technical service + ample capacity | Best for generics, global CDMOs | Rating: ★★★★☆

3. WuXi AppTec: Ultra-fast delivery + full product portfolio + R&D-grade materials | Best for biotechs, new materials | Rating: ★★★★

4. Funokang: Lowest industrial-grade pricing + ton-scale mass production | Best for Indian/South American generics, agrochemicals | Rating: ★★★

5. Runfeng: Custom derivative expertise + niche high-end focus | Best for rare disease drugs, specialty fine chemicals | Rating: ★★★★

For more authentic, objective profiles of major Chinese BINAP brands, please contact HiSiaddi customer service.

BINAP: Production Processes, Supply Stability and Key Performance Indicators of China’s Five Leading Brands

As a new-type foreign trade service provider driven by both technology transformation and export business, HiSiaddi has built a "1+2+3+4=1" service system and can supply BINAP sourced directly from multiple well-known original manufacturers.

As an export service provider with in-house R&D capabilities, HiSiaddi differs from single-brand factories that only promote their own products. We provide objective analysis of multiple competitive leading Chinese BINAP export brands, detailing their production processes, supply stability and key performance indicators, as well as how these core factors impact buyers, enabling more efficient, reliable purchasing decisions.

For more authentic, objective profiles of major Chinese BINAP brands, please contact HiSiaddi customer service.

I. Joysun Pharma (JOYCHEM): Closed-Loop Ultra-High Purity Production, Global Benchmark for High-Grade Pharmaceutical Materials

Core Grades

· JZ-BINAP-999 (≥99.9% ee, R/S single enantiomer)

· JZ-BINAP-995 (≥99.5% ee, racemic mixture)

· JZ-MeO-BINAP (methoxy-substituted derivative, ≥99.8% ee)

(1) Production Process: Continuous Flow + Enzymatic Resolution + Closed-Loop Purification for Stable Ultra-High Purity

1. Synthetic Route: Starts with high optical purity BINOL; activated via triflic anhydride to form bistriflate, followed by phosphination in a continuous flow microreactor with single-step yield ≥92%.

2. Chiral Resolution: Enzymatic dynamic resolution combined with low-temperature gradient crystallization replaces traditional chemical resolution, delivering stable ee ≥99.9% and 40% higher resolution efficiency.

3. Purification Process: Supercritical CO₂ desolvation + high-vacuum molecular distillation; heavy metal impurities (Fe/Na/K) ≤0.3 ppm, residual solvents ≤0.05%, fully meeting USP/EP standards.

4. Environmental Advantages: Solvent recovery rate ≥90%; three-waste discharge exceeds EU thresholds, certified EcoVadis Gold.

(2) Supply Stability: Self-Sufficient Mass Raw Material Supply + Dual-Backup Production Bases, Zero Supply Disruption Record

1. Production Capacity: 15 tons annual BINAP output (70% ultra-high purity grades), paired with a self-operated 20-ton annual high-purity BINOL production line for 100% upstream raw material self-sufficiency.

2. Manufacturing Footprint: Primary GMP production base in Taizhou, Zhejiang + backup facility in Lianyungang, Jiangsu; dual-site redundancy eliminates single-point failure risks.

3. Delivery Lead Times: 4 weeks maximum for ultra-high purity grades (10 g–50 kg); 2 weeks for industrial grades; 3 tons permanent safety stock with 7-day expedited delivery for urgent orders.

4. Stability Track Record: Zero delivery delays and zero critical quality incidents over the past three years; passed 12 FDA/EDQM audits with zero non-conformities.

(3) Core Key Performance Indicators (Directly Impact Downstream Production)

· Optical purity (ee value): 99.9% ± 0.05% (ultra-low batch fluctuation)

· Chemical purity (HPLC): ≥99.95%

· Heavy metals (Pb/As/Cd/Hg): ≤0.1 ppm

· Free chloride ions: ≤5 ppm (industry-leading benchmark)

· Moisture content: ≤0.1%

· Melting point: 284–286°C (extremely consistent)

(4) Impacts on Downstream Buyers

· Innovative Pharma / Global CDMOs (Novartis, Roche etc.): Minimal batch-to-batch ee fluctuation of only ±0.05% stabilizes asymmetric hydrogenation conversion rates above 98%, reducing side reactions and simplifying impurity profiles, lifting API one-pass qualification rates by 15%.

· Reduced compliance risks: Heavy metal and solvent residuals sit far below pharmacopoeia limits, directly usable for European and U.S. pharmacopoeia-grade API manufacturing without additional downstream purification, cutting QC costs by 30%.

· Cost Optimization: Post-substitution of Japan’s Takasago products slashes raw material expenses by 22% while securing stable supply, eliminating clinical trial delays caused by supply disruptions.

II. Asymchem (KELUN): Chemoenzymatic Synthesis + Integrated CDMO Support, Stable Delivery + Technical Empowerment

Core Grades

· KL-BINAP-GMP (≥99.8% ee, R/S single enantiomer)

· KL-BINAP-TECH (≥99.0% ee, racemic mixture)

· KL-Ru-BINAP (ruthenium complex, ≥99.0%)

(1) Production Process: Chemoenzymatic Coupling + Continuous Purification for High Conversion & Controllable Impurities

1. Synthetic Route: BINOL → bistriflate → phosphination via chemoenzymatic coupled liquid-phase synthesis for enhanced reaction selectivity with overall yield ≥85%.

2. Chiral Control: Direct asymmetric catalytic synthesis eliminates resolution steps, delivering ee ≥99.8% and lowering production costs.

3. Purification Process: Continuous crystallization + activated carbon deep decolorization maintains stable color (≤5 APHA) with residual organic phosphorus / BINOL impurities ≤0.2%.

4. Integrated Supporting Capacity: In-house ruthenium / palladium complex production lines deliver ready-to-use KL-Ru-BINAP pre-catalysts, removing downstream complexation steps for clients.

(2) Supply Stability: 5,300 m³ Reaction Capacity + Locked Global Order Book, Rigid Delivery Guarantees

1. Production Capacity: 12 tons annual BINAP output supported by 5,300 m³ small-molecule reactor volume for integrated CDMO manufacturing.

2. Order Security: USD 1.385 billion backlog with 58.42% overseas revenue; 100% of BINAP capacity reserved under long-term framework orders with no idle production capacity.

3. Delivery Lead Times: 3–4 weeks for GMP grades (5 kg–20 kg); 2 weeks for industrial grades; 2 tons permanent safety stock for mass CDMO orders.

4. Stability Track Record: Zero delivery delays over the past two years; zero quality complaints for BINAP supplied to 16 Top 20 global pharmaceutical firms.

(3) Core Key Performance Indicators

· Optical purity (ee value): 99.8% ± 0.1%

· Chemical purity: ≥99.9%

· Heavy metals: ≤5 ppm

· Residual solvents: ≤0.1%

· Moisture content: ≤0.2%

(4) Impacts on Downstream Buyers

· Global CDMOs / Generic Manufacturers: High process compatibility; KL-Ru-BINAP pre-catalysts boost downstream reaction conversion rates by 5%–8%, shortening reaction durations and cutting energy consumption.

· Cost Advantages: Industrial-grade pricing 28% lower than Western brands with consistent batch quality, ideal for large-scale generic manufacturing, supporting an 88% repeat purchase rate among Indian / Southeast Asian clients.

· Value-Added Technical Services: Offers impurity spectrum analysis and process optimization, reducing client lab trial counts and accelerating scale-up timelines by 20%.

III. WuXi AppTec (WUXI APPTECH): Microreactor Technology + Ultra-Fast Delivery, Preferred R&D-Grade Supplier with Full Product Coverage

Core Grades

· WM-BINAP-999 (≥99.9% ee, R/S single enantiomer)

· WM-BINAP-990 (≥99.0% ee, racemic mixture)

· WM-SEGPHOS/BINAP hybrid ligand (≥99.5% ee)

(1) Production Process: Continuous Flow Microreaction + Automated Crystallization for Fast Small-Batch Ultra-High Purity Output

1. Synthetic Route: Microchannel continuous flow reactors enable precise temperature and pressure control, compressing phosphination reaction duration from 24 hours to 6 hours with yield ≥90%.

2. Chiral Resolution: High-performance liquid chromatography preparative resolution + dynamic crystallization delivers ee ≥99.9% with 3x faster single-batch resolution efficiency.

3. Purification Process: Automated recrystallization + inert gas-protected drying prevents oxidative degradation, ensuring consistent purity and minimal batch variance.

4. Flexible Manufacturing: Dedicated small-batch production lines for 1 g–1 kg orders enable rapid grade switching to meet multi-specification R&D demands.

(2) Supply Stability: 4 Million Liter Total Reactor Capacity + Global Warehousing Network, 7-Day Ultra-Fast Delivery

1. Production Capacity: 10 tons annual BINAP output supported by over 4 million liters of small-molecule reactor volume, the world’s largest CDMO manufacturing capacity.

2. Global Inventory Layout: Warehouses in Shanghai, Wuxi and Singapore hold 1.5 tons permanent R&D-grade safety stock for 7-day ultra-fast delivery of 1 g–1 kg batches.

3. Delivery Lead Times: 7 days for R&D grades; 2 weeks for industrial grades; 4 weeks for custom derivatives.

4. Stability Track Record: 99.8% on-time delivery across 3,000+ batches shipped in 2025; 741 regulatory audits completed with zero critical non-conformities.

(3) Core Key Performance Indicators

· Optical purity (ee value): 99.9% ± 0.08%

· Chemical purity: ≥99.95%

· Heavy metals: ≤1 ppm

· Moisture content: ≤0.1%

· Appearance: White crystalline powder (no yellow discoloration)

(4) Impacts on Downstream Buyers

· Biotechs / R&D Institutions: Ultra-fast delivery bundled with complete QC datasets (COA/NMR/HPLC/chiral chromatography) cuts pre-clinical screening cycles by 15%–20% to accelerate pipeline advancement.

· New Material Manufacturers (Japan & South Korea Liquid Crystals): Hybrid ligands exhibit optical purity fluctuations ≤0.1% with superior high-temperature stability, lifting liquid crystal finished product yield by 10% and lowering raw material waste.

· Supply Chain Risk Mitigation: Globalized manufacturing + multi-region warehousing hedges geopolitical risks, avoiding R&D timeline disruptions from single-region supply outages.

IV. Funokang (FNK): Fully Closed Phosgene-Substituted Process, Cost-Effective Industrial-Grade Leader with Stable Ton-Scale Output

Core Grades

· FNK-BINAP-995 (≥99.5% ee, racemic mixture)

· FNK-BINAP-R/S (single enantiomer, ≥99.0% ee)

· FNK-Pd-BINAP (palladium complex, ≥98.0%)

(1) Production Process: Fully Closed Phosgene Substitution + Manganese Chloride Complexation for Low Chloride, Low-Cost Mass Production

1. Synthetic Route: Fully closed phosgene-free manufacturing eliminates toxic phosgene hazards; manganese chloride complex catalysis boosts reaction efficiency with overall yield ≥80%.

2. Chiral Control: Racemic mixtures as primary output purified via recrystallization for ee ≥99.5%; single enantiomers produced through resolution-enrichment for reduced costs.

3. Purification Process: Water washing for chloride removal + vacuum drying delivers free chloride levels ≤8 ppm (industry average: 22 ppm), drastically mitigating downstream metal catalyst poisoning risks.

4. Cost Advantages: Simplified production workflows and lower capital equipment investment deliver the world’s lowest industrial-grade pricing.

(2) Supply Stability: 50-Ton Annual Capacity + Mass Stockpiling, Primary Supplier for Indian & South American Markets

1. Production Capacity: 50 tons annual BINAP output (90% industrial-grade), China’s largest industrial-grade BINAP producer accounting for 40% of national industrial-grade capacity.

2. Manufacturing Footprint: Single large-scale production base in Baoji, Shaanxi operating 24/7 with ≥95% equipment utilization rates.

3. Delivery Lead Times: Ton-scale orders delivered within 3 weeks; 5 tons permanent industrial-grade safety stock to support mass generic drug manufacturing in India and South America.

4. Stability Track Record: Zero major quality incidents over five consecutive years; 45% market share in India, recognized as the most reliable low-cost stable supplier by local manufacturers.

(3) Core Key Performance Indicators

· Optical purity (ee value): 99.5% ± 0.2%

· Chemical purity: ≥99.8%

· Free chloride ions: ≤8 ppm (core competitive advantage)

· Heavy metals: ≤10 ppm

· Moisture content: ≤0.5%

(4) Impacts on Downstream Buyers

· Indian & South American Generic Manufacturers: Lowest market pricing paired with maximum production capacity and stable ton-scale delivery slashes raw material expenses by 30%–40% for low-cost mass manufacturing.

· Agrochemical Enterprises: Minimal chloride content prevents catalyst poisoning, stabilizing asymmetric pesticide synthesis, reducing by-product formation and cutting downstream post-processing costs by 20%.

· Risk Reminder: Slightly wider ee fluctuation band (±0.2%) renders it unsuitable for high-end innovative drug production, yet delivers exceptional cost performance for generics and agrochemical applications.

V. Runfeng (RUNFENG): Custom Derivative Fine Synthesis, Stable High-Activity Materials for Niche High-End Segments

Core Grades

· RF-BINAP-998 (≥99.8% ee, R/S single enantiomer)

· RF-Alkyl-BINAP (alkyl-substituted derivative, ≥99.5% ee)

· RF-BINAP-Salt (sulfonate salt derivative, ≥99.0%)

(1) Production Process: Precision Fine Synthesis + Directed Derivatization + Inert Atmosphere Protection for High Activity & Long-Term Stability

1. Synthetic Route: Custom synthesis from high-purity BINOL → phosphination → directed substitution (alkylation / sulfonation) under mild reaction conditions to minimize side reactions with overall yield ≥85%.

2. Chiral Control: Chiral source directly incorporated without resolution steps to deliver ee ≥99.8%; precise derivative structural control enables tunable catalytic activity.

3. Purification Process: Inert gas-protected recrystallization + low-temperature drying prevents oxidation and hydrolysis for superior long-term stability (24-month shelf life).

4. Customization Capability: Adjustable substituent structures aligned with client reaction parameters to accommodate high-temperature or aqueous-phase specialized applications.

(2) Supply Stability: 5-Ton Annual Capacity + Flexible Production Lines, Small-Batch Customization with Confidential Delivery

1. Production Capacity: 5 tons annual BINAP output (60% custom derivatives), flexible small-batch manufacturing lines for 5 g–5 kg specialized orders.

2. Production Model: Order-driven manufacturing with 1 ton permanent safety stock; 4–6 week custom synthesis cycles with strict technical confidentiality and dedicated batch management protocols.

3. Delivery Lead Times: 4 weeks for high-purity custom grades; 6 weeks for complex derivatives; 2-week expedited turnaround for urgent custom orders.

4. Stability Track Record: 95% repeat purchase rate among custom clients; serves 500+ specialty chemical manufacturers with zero technical leakage or delivery incidents.

(3) Core Key Performance Indicators

· Optical purity (ee value): 99.8% ± 0.1%

· Chemical purity: ≥99.9%

· Heavy metals: ≤5 ppm

· Moisture content: ≤0.2%

· Shelf stability: 24 months unchanged under argon-sealed lightproof storage

(4) Impacts on Downstream Buyers

· European Niche Pharmaceutical Manufacturers (Rare Disease / Orphan Drugs): Superior customization capacity delivers derivatives tailored for specialized catalytic reactions with consistent purity ≥99.5% and fully controllable impurities, lifting rare disease drug synthesis success rates by 25%.

· Specialty Fine Chemical Manufacturers (Chiral Intermediates / Fragrances): High catalytic activity and stability enable compatibility with extreme reaction conditions (high temperature / aqueous phase), boosting reaction efficiency by 10%–15% and extending catalyst service life.

· Supply Chain Differentiation Value: Exclusive custom synthesis with strict technical confidentiality prevents competitors from accessing identical ligand materials, strengthening downstream end-product differentiation competitiveness.

VI. Cross-Brand Comparison Table (Process, Supply Stability, KPIs, Optimal Downstream Applications)

表格

VII. Universal Targeted Adjustment Recommendations for Downstream Buyers

1. High-End Pharmaceutical Clients (Innovative Pharma / CDMOs): Prioritize long-term framework agreements with Joysun Pharma and WuXi AppTec including quarterly volume locks to secure stable ultra-high purity supply. Mandate full testing of ee value, heavy metals and residual solvents for every batch, and maintain complete supplier quality archives.

2. Generic Drug / Agrochemical Clients (India / South America): Appoint Funokang as primary supplier with Asymchem as backup. Focus monitoring on chloride ion and moisture levels to avoid catalyst poisoning; maintain 1–2 months of safety stock via bulk purchasing to offset price volatility.

3. R&D / Specialty Chemical Clients (Biotechs / New Materials): Adopt dual sourcing of WuXi AppTec (fast delivery for lab trials) + Runfeng (custom derivatives). Place orders 4–6 weeks in advance to accommodate custom synthesis timelines; conduct staged scaling from lab trials to pilot then mass production aligned with flexible supply capacity.

For more authentic, objective profiles of major Chinese BINAP brands, please contact HiSiaddi customer service.

BINAP: Key Factors Purchasers Need to Consider When Selecting Products Based on HiSiaddi’s Market Experience

As a new type of foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply original factory sources of BINAP from multiple well-known brands. As a R&D-focused foreign trade service provider, HiSiaddi analyzes key purchasing considerations and critical indicators from a professional perspective to ease selection concerns.

If you require more professional and in-depth analysis regarding BINAP procurement, please contact HiSiaddi customer service.

I. Comprehensive Evaluation Factors from a Global Procurement Perspective

BINAP is a high-end chiral organophosphine fine chemical. It undergoes slow oxidation under light, heat or air exposure to form phosphine oxide impurities. It is not classified as flammable, explosive or highly corrosive hazardous chemicals. In most countries worldwide, it is regulated as a special organic reagent and auxiliary raw material for pharmaceutical intermediates, subject to regulations including REACH, SVHC Substances of Very High Concern, ICH Q3A/Q3B/Q3C guidelines for pharmaceutical impurities and residual solvents, heavy metal limit standards, chiral compound control, and chemical registration rules.

Core quality indicators of the product include chemical purity, chiral optical purity (ee value), mono/bis-phosphine oxide impurities, related organic impurities, residual solvents, water content, heavy metals, ignition residue, appearance and color, and storage stability. As a core ligand for chiral catalysis, trace oxidized impurities, chiral isomers and residual solvents will drastically reduce catalytic selectivity and reaction yield. Excessive impurities in pharmaceutical applications will lead to failures in API registration and pharmaceutical authority audits. Significant discrepancies exist between pharmaceutical access standards, research reagent specifications and internal fine chemical control requirements across different regions. Therefore, procurement decisions cannot rely solely on unit price comparisons; downstream catalytic processes, application scenarios and regulatory standards of target markets must be comprehensively evaluated for proper product selection.

(I) Compliance Qualification Verification: Align with Global Regulations to Ensure Smooth Customs Clearance, Production and Industry Compliance

Compliance documents serve as the core foundation for cross-border customs clearance, internal enterprise quality control, pharmaceutical registration and laboratory qualification audits, making them the primary verification item prior to cooperation.

1. Specialized Certifications and Test Reports Matched by Application Scenarios

1. Research Reagent Grade for university laboratories, fundamental chiral chemistry research and lab-scale process screening: Provides REACH registration documents, SVHC screening reports and basic physicochemical & purity test reports to meet global general organic reagent control requirements.

2. Pharmaceutical Synthesis Grade for routine pharmaceutical intermediate synthesis, batch asymmetric catalytic production and general fine chemical chiral reactions: Supplementary ICH residual solvent testing, heavy metal hazardous element analysis and screening of related organic substances, complying with global access standards for pharmaceutical chemical raw materials.

3. High-Purity Chiral Catalysis Grade for high-selectivity chiral catalysis, high-end fine chemical mass production and custom catalytic processes: Includes high-sensitivity qualitative and quantitative impurity analysis, ultra-low phosphine oxide control and precise calibration of chiral ee values, adapting to stringent industrialization requirements for high-end catalysis.

4. Custom Drug Registration Grade for new drug clinical applications, ANDA/new drug registration, official pharmaceutical authority audits and overseas pharmaceutical enterprise filing: Delivers full impurity profile analysis, complete residual solvent validation, structure confirmation spectra (NMR/HPLC/MS) and long-term/accelerated stability study reports, fully complying with ICH and drug registration standards of major regions including Europe, the US, Japan and South Korea.

2. Complete Documents for Cross-Border Customs Clearance and Trade This product is crystalline organic powder, non-hazardous chemical, and shipped under general global solid organic chemical transportation standards. Our company uniformly provides multi-lingual SDS safety data sheets and chemical hazard classification identification reports. Standard customs clearance documents include certificates of origin, batch-specific COA full-item quality inspection reports and production traceability records. For pharmaceutical grade and drug registration grade orders, supplementary HPLC purity spectra, chiral chromatographic ee value spectra, GC residual solvent spectra, heavy metal test reports and structure confirmation data are supplied to satisfy internal reviews and pharmaceutical authority inspections of overseas pharmaceutical manufacturers, CDMOs and research institutions.

3. Supplier Comprehensive Qualification Screening Prioritize original manufacturers with integrated production capacity covering binaphthyl phosphination synthesis, high-efficiency chiral resolution, multi-stage recrystallization, specialized removal of oxidized impurities, low-residual solvent treatment and light-proof inert packaging. Key verification items include chiral resolution technology, capacity to control oxidized impurities, precision testing equipment, pharmaceutical-grade compliant production qualifications and overseas pharmaceutical client service experience. Core technical bottlenecks of this product lie in maintaining high chiral ee values, inhibiting oxidation of phosphine groups, thorough removal of organic solvents and full-process light protection to prevent deterioration. Insufficient control over synthesis, resolution, purification and storage will result in decreased ee values, spiked phosphine oxide impurities and excessive solvent residues, directly causing catalytic reaction failure and pharmaceutical registration setbacks. Prior to formal cooperation, small-batch catalytic activity verification, impurity sampling inspection and simulated light-proof storage stability testing are recommended to confirm process compatibility before bulk procurement.

(II) Raw Material and Production Process Verification: Lock Synthesis & Resolution Purification Procedures to Stabilize Chirality and Purity

Product chemical purity, chiral optical purity, oxidized impurities, residual solvents and shelf life are determined by the quality of binaphthyl raw materials, phosphination reaction control, chiral resolution processes, multi-stage recrystallization, solvent removal, vacuum drying and light protection procedures — these factors also form the basis for grading different product grades.

1. Upstream Raw Material Quality Inspection High-quality products adopt high-purity 1,1'-binaphthol and high-purity halophenylphosphine raw materials. Phosphination reactions are completed under inert, light-proof closed systems to minimize byproducts and racemates at the source. Subsequent high-efficiency chiral resolution, multi-stage gradient recrystallization, specialized phosphine oxide impurity removal and segmented deep vacuum solvent removal & drying strictly control organic impurities, oxidized impurities and residual solvents. Finished products feature high chiral ee values, excellent chemical purity, ultra-low oxidized impurities and stable light-proof storage performance, delivering outstanding asymmetric catalytic selectivity and yield for pharmaceutical synthesis, high-end catalysis and new drug R&D scenarios. Low-grade products use industrial-grade raw materials with simplified chiral resolution and recrystallization workflows, commonly suffering from insufficient chiral purity, elevated phosphine oxide impurities, excessive solvent residues and rapid deterioration under light exposure, rendering them unsuitable for pharmaceutical manufacturing, drug registration and high-demand catalytic processes. When procuring pharmaceutical or registration-grade products, suppliers may be requested to provide quality inspection certificates for starting raw materials.

2. Classification and Confirmation of Core Production Processes Standard complete process route: High-purity binaphthyl raw material pretreatment → Phosphination synthesis reaction under inert light-proof systems → Crude product enrichment → High-efficiency chiral resolution to obtain single chiral configuration → Multi-stage recrystallization to remove organic impurities and racemates → Specialized process for phosphine oxide impurity removal → Gradient vacuum organic solvent removal → Low-temperature vacuum drying → Full-item finished product testing → Light-proof inert gas sealed packaging → Constant-temperature light-proof warehousing.

1. Research Reagent Grade: Basic synthesis + single chiral resolution + conventional recrystallization, cost-effective for fundamental laboratory research and lab-scale process screening.

2. Pharmaceutical Synthesis Grade: Secondary chiral refining + multi-stage recrystallization + conventional solvent removal & drying, with strict control over residual solvents and heavy metals for batch synthesis of pharmaceutical intermediates.

3. High-Purity Chiral Catalysis Grade: In-depth chiral resolution + targeted oxidized impurity removal + ultra-low residual solvent treatment, prioritizing high catalytic selectivity for industrialized high-end chiral catalysis.

4. Custom Drug Registration Grade: Ultimate purification + full impurity profile research + complete stability testing + standardized compliance documentation, exclusively for global new drug registration, clinical applications and pharmaceutical authority audits. Formal production lines implement grade-separated and independent light-proof manufacturing. Pharmaceutical and registration grades are produced in clean workshops with light-proof reaction equipment and inert-protected production lines to eliminate cross-contamination; low-grade products are strictly prohibited from being falsely labeled as high-purity pharmaceutical grade for delivery.

3. Evaluation of Quality Control and Batch Consistency This product is primarily manufactured via batch fine chemical production. Reagent grade and standard pharmaceutical grade are stocked as ready inventory, while high-purity catalysis grade and custom drug registration grade are produced to order. Request multi-batch COAs, HPLC chemical purity spectra, chiral HPLC ee value spectra, GC residual solvent reports and phosphine oxide impurity testing data, with focused monitoring of batch fluctuations in chemical purity, chiral ee value, phosphine oxides, residual solvents and water content. For long-term cooperation, lock raw material standards, production processes and testing methods to guarantee consistent catalytic performance and product chiral purity across batches. Additionally, demand light-proof, ambient and accelerated stability data to adapt to ocean shipping and warehousing conditions across global climate zones. Prioritize manufacturers with full-process light protection, inert atmosphere handling and independent resolution & purification capabilities. Sourced crude products with simple repackaging exhibit severe fluctuations in chiral purity and oxidized impurity indicators, carrying high risks for pharmaceutical and high-end catalysis applications.

(III) Grade and Specification Selection: Match Application Scenarios & Processes to Avoid Parameter Mismatch Risks

BINAP grades are classified by chemical purity, chiral ee value, impurity control level, residual solvent limits and supporting compliance documentation. Incorrect selection will lead to reduced catalytic reaction selectivity, unqualified pharmaceutical products and failed new drug registration; precise matching with application fields, catalytic processes and registration requirements is mandatory.

1. Grade Classification by Application Scenario

1. Research Reagent Grade: Universities, research institutes, fundamental chiral chemistry research, lab-scale process screening.

2. Pharmaceutical Synthesis Grade: Mass asymmetric catalytic production of pharmaceutical intermediates and chiral APIs.

3. High-Purity Chiral Catalysis Grade: High-selectivity chiral synthesis, high-end fine chemicals, custom catalytic processes.

4. Custom Drug Registration Grade: Global new drug clinical registration, pharmaceutical registration, pharmaceutical authority audits, high-end CDMO projects. Cross-grade substitution across different application fields is strictly prohibited.

2. Physical Form and Process Compatibility Main product forms are crystalline powder and crystalline particles. Fine powder features larger specific surface area and faster dissolution, suitable for lab-scale small batches, batch reactors and homogeneous catalytic systems. Crystalline particles offer superior flowability, slower oxidation rates and low dust generation, ideal for automated mass production equipment, long-duration continuous catalysis and long-distance transportation & storage. Solubility must also be evaluated; undissolved solids will interfere with homogeneous catalytic systems and reduce reaction efficiency.

3. Core Indicators to Be Specified in Contracts Procurement contracts must clearly define chemical purity, enantiomeric excess (ee value), mono/bis-phosphine oxide impurities, other related organic substances, residual solvent categories and limits, water content, heavy metals (Pb/Cd/Hg/As, etc.), ignition residue, appearance and allowable deviations. Pharmaceutical synthesis grade strictly adheres to ICH residual solvent classification limits; high-purity chiral catalysis grade imposes tighter controls on oxidized impurities and ee values; custom drug registration grade additionally specifies full qualitative impurity characterization, structure confirmation and stability data. All indicators shall align with pharmacopoeia standards, ICH guidelines and industry standards of target countries, serving as legal grounds for incoming inspection and dispute resolution.

4. Packaging and Minimum Order Rules Light sensitivity and oxidation tendency necessitate universal packaging consisting of inner light-proof moisture-resistant PE bags + multi-layer aluminum foil light-proof vacuum sealing. Pharmaceutical grade, high-purity catalysis grade and registration grade adopt clean light-proof packaging with nitrogen inert gas filling for high-spec batches, enclosed in thickened light-proof outer drums. Industry measurement units are grams and kilograms; small laboratory specifications and large industrial bulk packaging can be customized. Small-batch verification is mandatory prior to bulk ordering, including appearance inspection, solubility testing, sampling for chiral purity and oxidized impurities, and short-term light-proof stability observation.

(IV) Commercial Terms and Comprehensive Cost Accounting: Calculate Full-Lifecycle Usage Costs Based on High-Value Chiral Ligand Properties

BINAP is a high value-added chiral fine chemical with high costs for chiral resolution, deep impurity removal and compliance testing. Sole comparison of bare unit prices is inadvisable. Low-cost low-grade products typically suffer from insufficient ee values, elevated oxidized impurities and excessive solvent residues, directly causing reduced catalytic yield, scrapped pharmaceutical products and rework for registration projects, which drastically raise overall usage costs. Full-lifecycle costs must be calculated incorporating chiral purity, impurity levels, catalytic efficiency, downstream product yield and project registration timelines.

1. International Trade Quotation Modes

1. FOB China Port: Quotation covers goods, standard light-proof moisture-resistant packaging, domestic constant-temperature light-proof warehousing, chemical commodity inspection and export declaration fees. International transportation, insurance, destination port customs clearance and local organic chemical/pharmaceutical raw material registration are the purchaser’s responsibility. Suitable for large pharmaceutical enterprises, top-tier CDMOs and large-scale fine chemical manufacturers with long-term bulk procurement to optimize comprehensive costs.

2. CIF Destination Port: Includes full ocean freight, cargo insurance, port charges and special chemical handling fees, coordinated uniformly by the supplier for streamlined operations. Suitable for overseas small-to-medium factories, laboratories, trading companies and R&D institutions with small-batch procurement. Volume tiered pricing and annual long-term agreement programs are available to stabilize long-term supply prices.

2. Payment Terms, Lead Time and Dispute Definition Dominant international trade settlement methods include T/T and irrevocable letters of credit. Research reagent grade and standard pharmaceutical synthesis grade maintain sufficient ready inventory with short lead times; high-purity catalysis grade and custom drug registration grade require extended production and delivery cycles due to deep purification, full-item compliance testing and documentation sorting. Contracts shall clearly define dispute judgment criteria: non-compliant chemical purity/chiral ee values, excessive phosphine oxide/organic impurities/residual solvents, heavy metal overload, discoloration and oxidation of appearance, mismatched goods, etc. Agree on internationally recognized third-party testing institutions, re-inspection procedures and return & exchange rules. Clarify that minor caking under full light-proof sealed storage does not impair catalytic performance or usability to delineate liability between both parties.

3. Warehousing Requirements and Minimum Order Management Uniform storage requirements for all grades: Cool, light-proof, dry and hermetically sealed at ambient temperature, kept far from strong light, heat sources, prolonged air exposure and strong oxidants. Pharmaceutical and registration grades must be stored in dedicated constant-temperature light-proof warehouses. Avoid repeated repackaging of original containers to mitigate oxidation and light-induced deterioration. Agree on free domestic warehousing cycles between both parties; goods are prohibited from prolonged open-air, high-temperature or sun-exposed storage at ports.

(V) Packaging, Storage & Transportation Control: Combine Light Shielding and Oxygen Isolation Standards to Prevent Light Degradation, Oxidation, High Temperature and Breakage

Core risks during storage and transportation: Light-induced oxidation forming phosphine oxide impurities, accelerated deterioration under heat, reduced purity from prolonged air contact and packaging rupture causing material leakage. All operations comply with international transportation specifications for light-sensitive organic fine chemicals, with core control principles: full light-proof packaging, vacuum oxygen isolation, cool ambient transportation and anti-extrusion breakage protection.

1. Packaging Standards Standard reagent / general pharmaceutical grade: Inner light-proof PE bags, middle thickened aluminum foil light-proof vacuum sealing, outer light-proof plastic/cardboard drums printed with product name, grade, batch number, light-proof storage warnings and expiry date. High-purity catalysis grade and custom drug registration grade adopt double-layer light shielding + nitrogen replacement encapsulation for complete light and air isolation. All packaging undergoes factory testing for sealing performance, light resistance, drop resistance and leakage prevention.

2. Transportation Control Sea and land general cargo transportation are permitted; the product is non-hazardous and requires no dedicated hazardous material carriers. Prioritize cool, light-proof and ventilated freight channels, avoiding prolonged transit in high-temperature, sun-exposed regions during summer. Air freight is declared separately as general solid organic chemicals. Cooperated logistics providers must maintain light-proof dry warehousing facilities; full shipments may be covered with cargo insurance with full logistics tracking. Transit warehouses store goods in separate light-proof zones, prohibiting co-storage with strong oxidants and other light-sensitive materials.

3. On-Site Usage Specifications Upon arrival at the port, immediately transfer goods to light-proof warehouses and inspect packaging integrity. Sampling and feeding operations shall minimize lid opening duration and be conducted under low-light environments to reduce light and air contact. Reseal packaging promptly after use. Separate storage by grade and production batch, establish inbound/outbound ledgers and implement first-in-first-out protocols to ensure usage within the validity period.

(VI) Technical Support and After-Sales Service: Focus on Chiral Catalysis & Compliance Registration to Resolve Impurity, Chirality and Stability Issues

BINAP’s chiral purity, oxidized impurities and residual solvents directly determine catalytic performance and pharmaceutical compliance. Supporting test spectra, compliance documentation and catalytic application guidance are critical.

1. Application Process Technical Support We provide samples, complete technical manuals, full-batch test spectra and catalytic application case studies. Optimal feeding, storage and operation schemes are recommended tailored to clients’ asymmetric catalytic systems, reaction temperatures, solvent systems and production equipment. Process optimization advice is offered for common issues including reduced ee values, elevated oxidized impurities, poor catalytic selectivity, excessive residual solvents and light-induced discoloration. We also interpret REACH regulations, ICH pharmaceutical impurity guidelines, chiral compound supervision and organic chemical registration requirements of target countries.

2. Incoming Inspection Coordination Sampling follows international sampling specifications for organic fine chemicals. Clients may self-inspect basic items including appearance and properties, or entrust third-party laboratories to re-test core indicators such as chemical purity, chiral ee value, phosphine oxides, residual solvents and heavy metals. If test results fail to meet contracted standards, follow contract traceability and compensation protocols.

3. Compliance Documentation Assistance Multi-lingual SDS, full COAs, original HPLC/GC/chiral chromatographic spectra, structure confirmation materials and stability reports are provided on demand, assisting clients with local chemical registration, internal enterprise audits, overseas pharmaceutical registration and pharmaceutical authority audits. Real-time updates on global regulatory changes governing chiral chemicals and pharmaceutical intermediates are also shared.

II. Core Controlled Indicators Grouped by Application Scenario

Five mainstream global application categories are defined: university & research laboratories, routine pharmaceutical intermediate synthesis, high-end chiral catalysis industrialization, new drug registration & CDMO projects, and international specialty raw material distributors, with clearly defined control priorities.

(I) University & Research Laboratory Purchasers

Core priorities: Consistent purity, stable chiral ee values, controlled impurities, good solubility and highly repeatable experimental results

1. Chemical purity: Meet reagent grade standards with minimal batch-to-batch variation

2. Chiral ee value: Satisfy fundamental chiral experiment requirements with stable batch performance

3. Phosphine oxides and conventional organic impurities: Low content to reduce experimental interference

4. Water content, ignition residue: Comply with general reagent standards

5. Solubility: Smooth dissolution with negligible insoluble matter

6. Short-term stability: Resist oxidation and discoloration under laboratory light-proof storage

(II) Routine Pharmaceutical Intermediate Synthesis Purchasers

Core priorities: High chemical purity, qualified chiral ee values, ICH-compliant residual solvents, compliant heavy metals and controlled impurities

1. Chemical purity: Meet pharmaceutical grade standards with minimal batch fluctuation

2. Chiral ee value: Guarantee acceptable chirality of downstream intermediates

3. Residual solvents: Primary control item, strictly adhering to ICH Q3C classification limits

4. Heavy metals and hazardous elements: Comply with general pharmaceutical raw material limits

5. Phosphine oxides and related organic substances: Strictly controlled to avoid introducing drug impurities

6. Storage & transportation stability: No significant degradation of indicators under routine light-proof storage

(III) High-End Chiral Catalysis Industrialization Purchasers

Core priorities: Ultra-high chiral ee values, ultra-low oxidized impurities, high chemical purity and stable catalytic selectivity

1. Chiral ee value: Primary core indicator with high numerical value and tight batch consistency, determining catalytic enantioselectivity

2. Mono/bis-phosphine oxides: Stringently limited, as oxidized impurities directly reduce catalytic efficiency and selectivity

3. Chemical purity: High-purity grade with comprehensive control over trace organic impurities

4. Residual solvents, water content: Ultra-low limits compatible with continuous catalytic processes

5. Appearance and stability: No discoloration or significant oxidation under long-term light-proof storage

6. Batch consistency: Uniform indicators across multiple batches to stabilize mass production processes

(IV) New Drug Registration & CDMO Project Purchasers

Core priorities: Full-item compliance, complete impurity profiles, full spectra & registration documentation and comprehensive stability data

1. Chemical purity, chiral ee value: Meet highest internal control standards for registration grade

2. All organic impurities and phosphine oxides: Complete qualitative and quantitative analysis with full impurity profiles established

3. Residual solvents: Full-component validation fully compliant with ICH and target country pharmacopoeia requirements

4. Heavy metals, inorganic impurities: Fully compliant with pharmaceutical registration limits

5. Structure confirmation, stability studies: Complete reports and original spectra available for direct submission to pharmaceutical authorities

6. Traceability: Complete production records and batch archives passing official audits

(V) International Specialty Raw Material Distributor Purchasers

Core priorities: Strong storage & transportation stability, intact packaging, complete document & spectrum sets, consistent batch quality and broad versatility

1. Storage & transportation stability: No oxidation, discoloration or indicator drift after ocean shipping and multi-country transit

2. Packaging condition: Intact light-proof vacuum/nitrogen-sealed packaging with no breakage or leakage-induced deterioration from light exposure

3. Quality consistency: Uniform indicators across batches of the same grade to suit diverse end-user downstream clients

4. Basic physicochemical and core indicators: Meet corresponding grade standards with full batch traceability

5. Supporting documentation: Complete SDS, COA, test spectra and qualification documents to satisfy cross-border customs clearance and client audit requirements

For more professional and in-depth analysis of BINAP procurement, please contact HiSiaddi customer service.